CD274 and head and neck squamous cell carcinoma: Furthermore, a pooled analysis of nine clinical trials of PD-(L)1 inhibitor monotherapy in advanced HNSCC demonstrated numerically higher but not statistically significant ORR (18.8 vs. 12.2%) and DCR (42.8 vs. 34.4%) for HPV-associated disease compared to HPV-negative disease [81].